HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Neragi-Miandoab, S. Search for Related Content PubMed PubMed Citation Articles by Neragi-Miandoab, S. Related Collections Lung - other Mediastinum Pleura Chest wall

Eur J Cardiothorac Surg 2006;29:14-19
© 2006 Elsevier Science NL

Review

Multimodality approach in management of malignant pleural mesothelioma

Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Chicago, Stritch School of Medicine, Maywood, IL, USA

Received 9 May 2005; received in revised form 28 September 2005; accepted 3 October 2005.

^_* Tel.: +1 617 223 7555. (Email: sneragi{at}yahoo.com).

Malignant pleural mesothelioma (MPM) is a solid, locally aggressive tumor, which has been closely linked to asbestos exposure. The survival rate without treatment ranges from 4 to 12 months. Response to chemotherapy and radiation is poor, and surgery is the most effective therapy. There are currently 3000 new MPM cases per year in the United States, with the peak incidence in the United States and Europe expected to occur in the year 2020. The prognosis depends on the stage of the tumor at the time of diagnosis, its histological type, lymph node status, and resection margins. While the diagnosis is often delayed, earlier intervention may improve life expectancy. Single-modality therapy has not been effective in changing the natural history of MPM. As a result, multimodality regimens involving surgery with radiation, chemotherapy, or immunotherapy have been initiated. Multiple modality approach has demonstrated favorable outcome, particularly in patients with epithelial histology, negative resection margins and presence of no metastases to extrapleural lymph nodes. Cisplatin and mitomycin have demonstrated modest efficacy in management of distant tumor recurrence. Cisplatin and gemcitabine regimen as well as cisplatin/pemetrexed followed by 54 Gy of adjuvant hemithorax radiation have been reported to improve the outcome.

Key Words: Multimodality treatment • Chemotherapy • Radiation • Supportive care • Immunotherapy • Gene therapy • PDT • Antiangiogenic therapy

This article has been cited by other articles:

				S. Neragi-Miandoab and D. J. Sugarbaker Chromosomal deletion in patients with malignant pleural mesothelioma Interactive CardioVascular and Thoracic Surgery, July 1, 2009; 9(1): 42 - 44. [Abstract] [Full Text] [PDF]

				B. D. Grigoriu, B. Chahine, A. Vachani, T. Gey, M. Conti, D. H. Sterman, G. Marchandise, H. Porte, S. M. Albelda, and A. Scherpereel Kinetics of Soluble Mesothelin in Patients with Malignant Pleural Mesothelioma during Treatment Am. J. Respir. Crit. Care Med., May 15, 2009; 179(10): 950 - 954. [Abstract] [Full Text] [PDF]

				S. Neragi-Miandoab, S. Weiner, and D. J. Sugarbaker Incidence of atrial fibrillation after extrapleural pneumonectomy vs. pleurectomy in patients with malignant pleural mesothelioma Interactive CardioVascular and Thoracic Surgery, December 1, 2008; 7(6): 1039 - 1042. [Abstract] [Full Text] [PDF]

				U. Donatella, N. Monica, C. P. Aldo, C. Cristina, C. Giuseppe, I. G. Paolo, L. Cecilia, M. Paola, P. Michela, P. Barbara, et al. The CREST Biorepository: A Tool for Molecular Epidemiology and Translational Studies on Malignant Mesothelioma, Lung Cancer, and Other Respiratory Tract Diseases Cancer Epidemiol. Biomarkers Prev., November 1, 2008; 17(11): 3013 - 3019. [Abstract] [Full Text] [PDF]

				G. L. Ceresoli, C. Gridelli, and A. Santoro Multidisciplinary Treatment of Malignant Pleural Mesothelioma Oncologist, July 1, 2007; 12(7): 850 - 863. [Abstract] [Full Text] [PDF]

				A. J. Holloway, D. S. Diyagama, K. Opeskin, J. Creaney, B. W.S. Robinson, R. A. Lake, and D. D.L. Bowtell A Molecular Diagnostic Test for Distinguishing Lung Adenocarcinoma from Malignant Mesothelioma Using Cells Collected from Pleural Effusions Clin. Cancer Res., September 1, 2006; 12(17): 5129 - 5135. [Abstract] [Full Text] [PDF]